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Despite the role of the estrogen receptor a (ERa) pathway as a key growth driver for breast cells, the
phenotypicconsequenceofexogenousintroductionofERaintoERa-negativecellsparadoxicallyhas
been growth inhibition. We mapped the binding proﬁles of ERa and its interacting transcription
factors (TFs), FOXA1 and GATA3 in MCF-7 breast carcinoma cells, and observed that these three
TFs form a functional enhanceosome that regulates the genes driving core ERa function and
cooperatively modulate the transcriptional networks previously ascribed to ERa alone. We
demonstrate that these enhanceosome occupied sites are associated with optimal enhancer
characteristics with highest p300 co-activator recruitment, RNA Pol II occupancy, and chromatin
opening. Most importantly, we show that the transfection of all three TFs was necessary to
reprogramme the ERa-negative MDA-MB-231 and BT-549 cells to restore the estrogen-responsive
growth resembling estrogen-treated ERa-positive MCF-7 cells. Cumulatively, these results suggest
that all the enhanceosome components comprising ERa, FOXA1, and GATA3 are necessary for the
full repertoire of cancer-associated effects of the ERa.
Molecular Systems Biology 7: 526; published online 30 August 2011; doi:10.1038/msb.2011.59
Subject Categories: functional genomics; chromatin and transcription
Keywords: enhanceosome; estrogen receptor a; FOXA1; GATA3; synthetic phenotypes
Introduction
Estrogen receptor a (ERa) is a member of the nuclear receptor
superfamily that has broad impact on systems such as
reproduction, cancer, bone, and cardiovascular biology.
The basic regulatory function of ERa is to bind to its DNA
recognition sequence also known as estrogen-response ele-
ments (EREs). The direct DNA binding, though necessary, is
not sufﬁcient to explain ERa-directed gene regulation. ERa
recruits avarietyof co-activators,corepressors,and chromatin
remodelingenzymestothepromoterandenhancerregionsbut
the range of possible combinations at each individual site and
their distances from the transcription start sites (TSSs) of
regulated genes suggest multiple regulatory mechanisms
(Farnham, 2009). ERa is also known to commonly induce
long-distance chromatin interactions with ERa binding sites
and with TSS through chromatin looping (Fullwood et al,
2009), suggesting that higher dimensional structural order
beyond the simple receptor–recognition motif interaction is
essentialinexplainingERa-directedtranscriptionalregulation.
The ﬁnding that transcription factors (TFs) cluster at
juxtaposed binding sites in the genome to form enhanceo-
somes further suggests that the totality of gene regulation by
any TF will be dependent on a complex interaction between
speciﬁc ERa binding, local conﬁguration of co-occupying TFs,
protein cofactors, chromatin conditions, and three dimen-
sional interactions.
ERa is known as a ligand-activated TF that mediates the
proliferative effects of estrogen (E2) in breast cancer cells.
However, some physiologic and cellular contradictions have
been previously noted in ERa biology. Garcia et al (1992)
showed that the transfection of the ERa alone into ERa-
negative cell lines has commonly no growth effect or even
repress growth. This is also true for an important ERa-
associated TF, FOXA1, where introduction of this gene
represses cell growth (Wolf et al, 2007). We posited that these
higher order regulatory mechanisms of ERa function such as
theformationandcompositionofenhanceosomesmayexplain
the establishment of transcriptional regulatory cassettes
favoring either growth enhancement or growth repression.
In our previous (Lin et al, 2007) and recent (Joseph et al,
2010) studies, we have identiﬁed high conﬁdence ERa binding
sites in MCF-7 humanmammarycarcinomacells.With known
motif scanning and de novo motif ﬁnding methods, we
identiﬁed that FOXA1 and GATA3 motifs were commonly
enriched within ERa binding sites. FOXA1 has been exten-
sivelystudiedinthecontextofERabiologyanditisconsidered
as a pioneering factor which prepares genomic sites for ERa
binding (Cirillo et al, 2002). GATA3 has been found to be an
essential TF for luminal development in mouse mammary
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microarray studies have documented the co-expression of
ERa, FOXA1, and GATA3 in primary breast tumors (Badve
et al, 2007; Wilson and Giguere, 2008). Though this evidence
suggests that the three TFs, ERa, FOXA1, and GATA3 may
clusteronDNAbindingsitesandmay beinvolvedinthebreast
cancer phenotype, there is little understanding as to the nature
of their coordinated interaction at the genome level or the
biological consequences of their detailed interaction.
In the present study, we investigate the ERa-mediated
transcriptional networks orchestrated with FOXA1 and GATA3
inbreastcancercells.Weusechromatinimmunoprecipitation-
sequencing (ChIP-seq) to deﬁne the binding proﬁles of ERa,
FOXA1, and GATA3 as to study the interplay among these TFs.
We aim to dissect the roles of FOXA1 and GATA3 in regulating
ERa action; to map the genomic effects of ERa, FOXA1, and
GATA3 in altering the transcriptional activation in breast
cancer cells; and to determine if FOXA1 and GATA3 are
essential components of ERa-induced proliferation in breast
cancer cells in response to estrogen stimulation.
Results
Mapping the binding proﬁles of ERa, FOXA1,
and GATA3
We mapped the genome-wide in vivo binding sites of ERa,
FOXA1, and GATA3 using the massively parallel ChIP-seq in
MCF-7cellsbeforeandafterestradiolexposure.Usingthepeak
callingalgorithmMACS(Zhangetal,2008),wefoundatotalof
1990 high conﬁdence ERa binding sites, 9337 FOXA1 binding
sites, and 20707 GATA3 binding sites in the vehicle-treated
cells (i.e., without ligand). Upon E2 stimulation, we found a
total of 19412 high conﬁdence ERa binding sites (an increase
of B16.58-fold after normalization of library size, see details
in Supplementary information and Supplementary Table I),
15852 FOXA1 binding sites (an increase of B2.46-fold
after normalization), and 38530 GATA3 binding sites
(an increase of B1.32-fold after normalization). Validation
of randomly selected binding sites using ChIP-qPCR showed
100% concordance in calling bound sites (Supplementary
Figure S1) and quantitatively, the ChIP-qPCR results for
FOXA1 and GATA3 binding sites correlated well with the
binding intensity measured by ChIP-seq (correlation coefﬁ-
cient R¼0.63–0.81, see Supplementary Figure S1).
To assess how these TFs individually interact, we over-
lapped their binding proﬁles and found 37% of B19k ERa
binding sites showed FOXA1 colocalization, 45% of ERa
binding sites overlapped with GATA3 binding sites, and as
much as 30% of ERa binding sites were co-occupied by both
FOXA1 and GATA3 (Figure 1A). Interestingly, the number
of sites with occupancy of all three TFs increased from 342
(before estradiol exposure) to 5876 (after estradiol exposure).
Figure 1B revealed that FOXA1 and GATA3 bindings are
symmetrically distributed within 200bp around the 5876 ERa,
FOXA1, and GATA3 conjoint binding sites. The relative
intensity of bindings as measured by TF occupancy at
these conjoint sites highly correlated among the three TFs
(R¼0.48–0.63, Supplementary Figure S2). These results
suggest that ERa, FOXA1, and GATA3 bind in a coordinated
manner at B30% of all ERa binding sites after stimulation
by ligand.
Motif analyses of the TFs binding
In order to determine the in vivo sequences enriched in the
ERa, FOXA1, and GATA3 occupied sites, we used an in-house
program CentDist (Zhang et al, 2011) for known motif
scanning. This program not only allows for the identiﬁcation
of speciﬁc binding motifs, but also displays the position-
distribution around the binding sites to indicate binding
speciﬁcity. The motif position weight matrixes (PWM) from
TRANSFAC (Matys et al, 2003) version 11.3 were used and the
cutoff of PWM score was set to 1E 3. As expected, we found
signiﬁcant enrichment of individual ERE, FOXA1, and GATA3
motifs in the ERa, FOXA1, and GATA3 ChIP-seq libraries,
respectively (Figure 1C–E). We also observed that the three
ERE, FOXA1, and GATA3 binding motifs emerged together as
thetop enriched motifs in eachset of theindividual TFbinding
sites, suggesting a bias for recognition motifs for all three
factors to be clustered together (Figure 1C–E). Besides FOXA1
andGATA3motifs,AP1andBACHmotifswerealsoenrichedin
the ERa binding sites, which is in agreement with the previous
ﬁnding reported by Bhat-Nakshatri et al (2008). Because of
prior genetic data suggesting a role for FOXA1 and GATA3 in
breast biology, we pursued the interaction of these three
factors.
We speciﬁcally assessed the frequency of ERE, FOXA1, and
GATA3 binding motifs around ERa binding sites. Figure 1F
shows that 72% of the ERa sites have an ERE motif, 71% of
ERa sites contain a FOXA1 motif, 43% of ERa sites contain a
GATA3motif,and23%oftheERasitescontainallthreemotifs.
Next, we asked whether these factors are physically coloca-
lized. Using sequential ChIP followed by qPCR in randomly
selected sites conjointly occupied by ERaþFOXA1 and
ERaþGATA3, we found cooccupancy of these TFs at the
overlap binding sites (Figure 2). These results suggest that the
colocalization of the three factors at ERa occupied sites
occur primarily through sequence recognition and not solely
throughatetheringmechanisminvolvingonlyprotein–protein
interaction.
Progressive recruitment of ERa and FOXA1
to the cis-regulatory elements
It was previously described that FOXA1 is a pioneering factor
characterized by this sequence of events: FOXA1 binds to
the condensed chromatin in the absence of E2 and opens the
chromatin to facilitate the ERa binding upon E2 stimulation
(Carroll et al, 2005; Hurtado et al, 2011). In addition, it was
reported that FOXA1 bound at ERa sites before ligand
stimulation followed by diminished FOXA1 occupancy after E2
exposure potentially through displacement by the activated ERa
(Carroll et al, 2005). However, we observed both an increase in
the number of FOXA1 binding sites (9337–15852) and in the
average level of occupancy at each site after ligand stimulation
(on average, there were 2.58 reads per peak per million reads in
the FOXA1 ChIP-seq library after E2 stimulation compared with
1.74 reads per peak per million reads before E2 stimulation).
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after E2 stimulation were co-occupied by FOXA1 where 25%
(508/1990)oftheERabindingsitesintheabsenceofligandwere
co-occupied by FOXA1 (Figure 3A). This is in accordance with
the earlier observations that FOXA1 is preferentially associated
with E2-bound ERa (Zhao et al, 2001).
If FOXA1 was a true pioneering factor, FOXA1 occupancy
wouldbepresentinasigniﬁcantpercentageofERaboundsites
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Figure 1 The repertoire of ERa, FOXA1, and GATA3 in vivo bindings by massively parallel ChIP-seq approach. (A) Venn diagrams of in vivo bindings for ERa,
FOXA1, and GATA3 upon and before E2 stimulation in MCF-7 cells. (B) The distance distribution of FOXA1 and GATA3 bindings around ERa sites, demonstrating that
FOXA1 and GATA3 have similar distance distribution around ERa sites. (C–E) Motif scanning around ERa, FOXA1, and GATA3 peaks separately. (F) The distribution
of ERa, FOXA1, and GATA3 motifs around ERa binding sites.
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only 11% (2218/19412) of E2-induced ERa sites are occupied
by FOXA1 before ligand exposure (Figure 3A). When we
eliminate the number of basal ERa-bound sites before E2
stimulation, the percentage of FOXA1 sites that can recruit
ERais19%(¼(130þ1598)/9337).ThismeansthatFOXA1isa
potential pioneering factor to recruit only a subset of ERa
binding sites.
Interestingly, view from a different prospective, after
excluding the number of basal FOXA1-bound sites before E2
stimulation,thepercentageofERasitesthatcanrecruitFOXA1
after E2 exposure is 29% (¼(573þ9)/1990). Thus, ERa can
also ‘pioneer’ a site for FOXA1 as efﬁciently as the converse
even though, because of a much larger starting denominator
(9337 sites versus 1990), it appears that FOXA1 is a better
pioneering factor.
To conﬁrm this ChIP-seq-based observation, we synchro-
nized the cells with a-amanitin treatment followed by
E2 stimulation and performed ChIP-qPCR over time on the
nucleus lysates. In the sites where FOXA1 functions as the
recruiting factor, we observed enrichment of FOXA1 occu-
pancy as early as 5min, followed by progressively increasing
ERa occupancy at the later time points (e.g., after 10–15min,
example in Figure 3B). Conversely, in those sites where
ERa functions as the recruiting factor, we show high ERa
occupancy at early time points followed by increasing FOXA1
occupancy at the later time points (example in Figure 3C).
Thus, we show that ERa and FOXA1 can equally function
as recruiting factors for the other.
The formation of enhanceosome consisting of
ERa, FOXA1, and GATA3 in breast cancer cells
We have observed the colocalization of ERa, FOXA1, and
GATA3 at genomic sites after ligand stimulation. We then
wished to assess the dynamics of this recruitment by the three
TFs in response to E2 stimulation. First, we grouped the
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Figure 2 The interaction between ERa, FOXA1, and GATA3 in breast cancer genome. The co-occupancy of ERaþFOXA1 (A) and ERaþGATA3 (B) to the target
cis-regulatory regions as validated by sequential Re-ChIP assay. Genes nearby are used to label the peaks, and the tag densities around gene GPR37L1 with
ERaþFOXA1 peaks and gene ZMYND8 with ERaþGATA3 peaks are shown as examples. A site near LRRN6A gene with only unique ERa binding is recruited as a
negative control for the sequential Re-ChIP assay. The ChIP enrichment was computed by comparing with the IgG pull-down control. Mean values of at least two
independent experiments are compared and standard errors are shown.
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ERa unique, FOXA1 unique, GATA3 unique, ERaþFOXA1
overlap, ERaþGATA3 overlap, FOXA1þGATA3 overlap, and
ERaþFOXA1þGATA3 overlap sites as shown in the Venn
diagram of Figure 1A. We investigated how these different
subsetsofTFbindingsclusteredafterE2stimulation.Wefound
(Figure 4A) a dramatic shift of single and double TF binding
sites to sites occupied by the three TFs: 489% of vehicle-
treated ERaþFOXA1 overlap sites, 86% of ERaþGATA3
overlap sites, 30% of ERa unique site, and 28% of the
FOXA1þGATA3 overlap sites were shifted to the ERaþ
FOXA1þGATA3 overlap sites in response to E2 induction. By
contrast, the FOXA1 unique and GATA3 unique sites (before
ligand) showed little to no shift to the conjoint three factors
occupancystate after E2 treatment.This suggests that estradiol
activation induces the recruitment of FOXA1 and GATA3 with
ERa at ERa binding sites.
It has been previously shown that the functional utilityof an
ERa binding site is higher when these sites are marked by
speciﬁc and quantitative chromatin signatures: functionally
activesites havehigherERa occupancy,moreopen chromatin,
and more likely to show p300 and RNA Pol II occupancy
(Figure 4; Supplementary Figure S3). Figure 4B–D shows that
the normalized tag proﬁles of ERa, FOXA1, and GATA3 at the
bindingsites arestronglyenriched after E2 treatment forall the
above marks with the ERaþFOXA1þGATA3 overlapping
conjoint sites having the highest tag occupancy proﬁle above
all other colocalized categories. In addition, the triple TF
overlap sites show the greatest occupancy of each individual
TF. p300 co-activator possesses intrinsic histone acetyltrans-
ferase activity capable of modifying the chromatin organiza-
tion and facilitating transcriptionalinitiation (Heintzman et al,
2007), and p300 enrichment is commonly found at the
enhancer regions. We observed ERaþFOXA1þGATA3 over-
lap sites have the highest p300 co-activator occupancy
(Figure 4E). Previously, we have determined that RNA Pol II
co-bindingatERabindingsitesisrelatedtodistantinteractions
linkingtheenhancersiteswiththeTSSs(Fullwoodetal,2009).
In Figure 4F, we show that ERaþFOXA1þGATA3 overlap
siteshavethehighestRNAPolIIoccupancywithERaþFOXA1
double overlap sites following closely. When the chromatin
state was assessed by formaldehyde-assisted isolation of
regulatory elements (FAIRE) (Joseph et al, 2010), we found
that ERaþFOXA1þGATA3 and ERaþFOXA1 overlap sites
have the highest association with chromatin opening
(Figure 4G). This suggests that these triple overlap sites
(ERaþFOXA1þGATA3) are potentially the most active
enhancers affecting ERa transcriptional regulation and that
there appears to be a hierarchy of associative effect: FOXA1
contributing the most to ERa enhancer function and GATA3
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independent of ERa occupancy intensity since the triple
overlap/enhanceosome sites (ERaþFOXA1þGATA3) bear
the marks for optimal enhancer with the highest p300
occupancy while the non-enhanceosome sites have less
association with the enhancer marks though all these sites
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intensity (Supplementary Figure S4).
It is known that TFs can interact through long-range
chromatin interactions to regulate the transcriptional net-
works. Recently, a new method known as Chromatin Interac-
tion Analysis with Paired-End-Tag sequencing (ChIA-PET) has
been developed (Fullwood et al, 2009; Li et al, 2010) to
characterize the long-range chromatin looping mediated by
ERa in MCF-7 cell line. After re-analyzing the ERa ChIA-PET
data, we observed that 81% of the 5067 interaction clusters
haveatleastoneanchorregion(anERabindingsiteassociated
with a distant chromatin interaction forming at least one loop)
characterized by ERaþFOXA1þGATA3 colocalization.
Furthermore, the interaction clusters from ChIA-PETcan form
complex clusters that organize the local genomic region into
multiple loops. These complex interaction clusters also
demarcatethemostsigniﬁcantERa-regulatedgenes(Fullwood
et al, 2009). Of the 5067 ERa-mediated long-range interaction
clusters, 4500 clusters are involved in complex interaction
clusters and 567 clusters are involved in duplex interaction
clusters. In all, 88% of the complex interaction clusters are
associated with ERaþFOXA1þGATA3 overlapped binding
sites, while 51% of the duplex interaction clusters have the
support of ERaþFOXA1þGATA3 overlapped binding sites
(Supplementary Figure S5). Since complex interaction clusters
mark genes most responsive to E2 as compared with duplex
clusters, these data support the notion that the presence of the
ERa, FOXA1, and GATA3 putative enhanceosome is associated
with genes that are most responsive to E2. A speciﬁc example
of the ERa-mediated long-range interactions involving
conjoint ERa, FOXA1, and GATA3 binding sites around the
highly E2-responsive GREB1 gene is shown in Supplementary
Figure S5. These triple TF conjoint binding sites are highly
represented at the sites involved in frequent long-range
chromatin interactions spanning 50kb.
The impact of TFs binding on gene expression
We have provided evidence that the clustering of ERa, FOXA1,
and GATA3 at ERa binding sites is associated with chromatin
characteristics of the most active ERa enhancers. To assess the
effect of this enhanceosome presence on direct gene regula-
tion, we performed a detailed microarray expression analysis
to determine E2-responsive genes in MCF-7 cells. We found a
total of 653 upregulated and 1249 downregulated genes in
responsetoE2stimulation(SupplementaryTablesVIIIandIX).
We assigned a speciﬁc known gene to a binding site occupied
by any combination of the three TFs if the peak of each
TF category is the nearest and within 20kb of TSS of that
E2-responsive gene (see Supplementary information).
Figure 5A shows that, for the genes with ERa, FOXA1, and
GATA3 peaks or any combination, the biggest proportion of
either upregulated or downregulated genes is from genes with
adjacent ERaþFOXA1þGATA3 conjoint binding sites within
20kb of their TSS (28 and 30%, respectively). Since the
different binding sites are present in the genome at different
frequencies, the ratio of regulated versus non-regulated genes
for each binding site class can be used to normalize the
differences. The proportion of upregulated genes with ERa,
FOXA1, and GATA3 conjoint peaks is 2.3-fold of the
non-regulated genes with the same conﬁguration. This is
contrasted by genes adjacent to other combinations of ERa,
FOXA1, and GATA3 binding which do not show signiﬁcant
changes as compared with non-regulated genes. The only
exception is the proportion of genes close to FOXA1þGATA3
co-bound sites, which are associated with greater down-
regulated genes. Despite this association, the percentage of
downregulated genes putatively controlled jointly by FOXA1
andGATA3isrelativelysmall.Finally,thepresenceofthethree
TFs relative to a regulated gene may have two conﬁgurations:
one where the ERa binding site has conjoint and therefore
overlapping occupancy by all three TFs, and the other where
the binding of the individual TFs is in proximity with each
other and within 20kb of a gene, but the binding sites are not
overlapping (Figure 5B; see Supplementary information).
When we analyzed the association of E2-regulated genes with
these two categories (overlapping and non-overlapping),
we found that the predominant association is between the
conjoint binding sites and regulated genes (Figure 5B). Our
results imply that ERa regulation of gene expression is closely
linked to adjacency with sites that show conjoint binding with
ERa, FOXA1, and GATA3 putatively forming an enhanceo-
some. Using Gene Ontology analysis (Thomas et al, 2003), we
sought to further ascertain the importance of genes in
proximity with enhanceosome binding as compared with
binding of the individual TF components. We found that only
genes associated with ERaþFOXA1þGATA3 binding have
signiﬁcant association (with P-values up to 6.7E 26) with
speciﬁc biology processes known to be involved in ERa
signaling (e.g., signal transduction and cell proliferation),
molecular function (e.g., kinase and protein binding), and
signaling pathways (e.g., PDGF signaling pathway, inﬂamma-
tion mediated by chemokine and cytokine signaling pathway)
(Figure 5C; Supplementary Tables II and III). Thus, the
identiﬁcation of the ERa enhanceosome-associated genes
allows for the identiﬁcation of a ‘core’ set of ERa-regulated
genes that are strongly associated with the cognate cellular
functions previously known for ERa.
To further validate that ERaþFOXA1þGATA3 co-binding
represents an optimal conﬁguration for E2-mediated transcrip-
tionalactivation,wehaveperformedluciferasereporterassays
on GREB1 locus that actively engages ERa enhanceosome sites
in gene regulation. We cloned the promoter region of GREB1
that includes an ERaþFOXA1þGATA3 enhanceosome bind-
ing site into the pGL4-luciferase reporter construct and then
transfected GREB1-luciferase promoter construct into ER-
negative MDA-MB-231 cells, followed by transfection and
overexpression of ERa, FOXA1, and/or GATA3. The individual
presence of FOXA1 and GATA3 or combination of both only
produced subtle changes to the GREB1 luciferase activity,
demonstratingthatthepresenceofFOXA1andGATA3alone or
combination of both do not activate the transcription of
GREB1 gene (Figure 5D). The presence of ERa induced the
GREB1 luciferase activity to B246% (as compare with the
control construct). The combination of ERaþFOXA1 and
ERaþGATA3 has increased the luciferase activity to B330%
(an increment of 26–32%). Interestingly, the assemblage of
ERaþFOXA1þGATA3 provided the optimal ER responsive-
ness to 370% representing an additional 12–14% increment.
This suggests that ERa provides the fundamental gene
Enhanceosome-mediated transcription networks
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improve ERa-regulated transcriptional induction.
Such artiﬁcial transfection reporter systems accentuate TF
responses because of unnatural stoichiometries of the TFs.
To further assess the interplay among ERa, FOXA1, and
GATA3, we perturbed the binding of these TFs in MCF-7 cells
through the site-directed mutagenesis assay and asked
whether the loss of individual binding motifs would alter
3.58
1.88
2.65 2.45
2.08
1.30* 1.09*
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
I
n
d
u
c
t
i
o
n
Transfected constructs
The luciferase activity of GREB1 gene  
repressed by mutations of ER , FOXA1, and 
GATA3 in MCF-7 
0.87
2.13 *
0.79
1.07
2.81* 2.87*
0.71
3.20*
0
0.5
1
1.5
2
2.5
3
3.5
4
I
n
d
u
c
t
i
o
n
Transfected constructs
The luciferase activity of GREB1 gene induced by 
ER , FOXA1, and GATA3 in MDA-MB-231
0%
5%
10%
15%
20%
25%
30%
ER+FOXA1+GATA3 
(non overlap)
ER+FOXA1+GATA3 
(overlap)
P
e
r
c
e
n
t
a
g
e
 
o
f
 
g
e
n
e
s
w
i
t
h
 
b
i
n
d
i
n
g
 
s
i
t
e
s
Association of ER+FOXA1+GATA3 binding 
sites with E2-regulated genes
0%
ER unique
ER+FOXA1
ER+GATA3
FOXA1+GATA3
ER+FOXA1+GATA3
FOXA1 unique
GATA3 unique
5%
10%
15%
20%
25%
30%
35%
P
e
r
c
e
n
t
a
g
e
 
o
f
 
g
e
n
e
s
w
i
t
h
 
b
i
n
d
i
n
g
 
s
i
t
e
s
 
Association of binding sites with E2-regulated genes
Upregulated genes Downregulated genes Non-regulated genes
A
Note: * means that the P-values are 1E–14 from exact 
fisher test
*
*
*
**
*
Biological process
Genes with 
ER+FOXA1+GATA3 
overlapped peaks (P-value)
Genes with ER unique 
peaks (P-value)
Genes with FOXA1 
unique peaks (P-value)
Genes with GATA3 unique
peaks (P-value)
Cellular process 6.71E–26 1.14E–05 NS 1.61E–07
Cell communication 1.48E–19 8.06E–08 NS 9.69E–05
Developmental process 2.08E–19 NS NS NS
Signal transduction 1.58E–17 6.34E–08 NS NS
System development 7.60E–13 NS NS NS
Intracellular signaling cascade 1.75E–12 NS NS NS
System process 3.44E–12 NS NS NS
Cell motion 3.61E–12 NS NS NS
Ectoderm development 1.02E–11 NS NS NS
Cellular component morphogenesis 3.96E–11 NS NS NS
Anatomical structure morphogenesis 3.96E–11 NS NS NS
Transport 3.96E–11 NS NS NS
Neurological system process 4.17E–11 NS NS NS
Nervous system development 1.69E–10 5.95E–05 NS NS
Cellular component organization 1.20E–09 NS NS NS
Cell adhesion 2.31E–09 NS NS NS
Mesoderm development 4.05E–09 NS NS NS
Sensory perception 1.06E–08 NS NS NS
B
NS = not significant with P-value larger than 1E–04
C
D
Note: * means that the P-values 0.05 from one-side t-test
E
ER+FOXA1+GATA3
ER+FOXA1+GATA3
mER+FOXA1+GATA3
ER+mFOXA1+GATA3
ER+FOXA1+mGATA3
ER+mFOXA1+mGATA3
mER+mFOXA1+GATA3
mER+FOXA1+mGATA3
FOXA1+GATA3
ER+FOXA1
ER+GATA3
GATA3
FOXA1
ER
Non
Enhanceosome-mediated transcription networks
SL Kong et al
8 Molecular Systems Biology 2011 & 2011 EMBO and Macmillan Publishers Limitedgene regulation under physiologic concentrations of the three
TFs. Different GREB1-luciferase constructs with mutated ERE,
FOXA1, or GATA3 motif at the speciﬁc ERa, FOXA1, and
GATA3 binding sites were generated. The results revealed that
individually mutated FOXA1 or GATA3 motif only imposed
25–30% loss of GREB1 luciferase activity (Figure 5E). Mutated
ERE alone has repressed the luciferase measurement
to B50%. Interestingly, combinatorial EREþFOXA1 and
EREþGATA3 mutation further reduced the luciferase activity
by B65–70%, suggesting that the effects of the individual TFs
on this putative enhanceosome are additive. Here, we can
buildahierarchyofTFscontrol,showingthatERaaccountsfor
50% of the transcriptional control while FOXA1 and GATA3
individually account for another 20% transcriptional control
at the GREB1 gene regulatory locus.
FOXA1 and GATA3 are essential co-regulators
in mediating the ERa-growth response
It is known that ERa is a ligand-activated TF that mediates the
proliferative effects of E2 in breast cancer cells. Garcia et al
(1992) showed inhibited growth in MDA-MB-231 cells with
forced expression of ERa upon E2 treatment. The rationale for
these different outcomes has remained elusive. We hypothe-
size that the absence of critical co-regulators such as FOXA1
and GATA3 is responsible for the ERa-response cassette.
To test this hypothesis, we stably transfected the MDA-MB-
231 cells with individual ERa, FOXA1, GATA3, or in combina-
tion. The induction of ERa, FOXA1, and GATA3 expressions
following transfections was veriﬁed (Supplementary Figure
S6). The cell proliferation in response to E2 stimulation was
measured using two assays: WST-1 and cell count using
Hoechst stain. In parallel to the report by Garcia et al (1992),
we observed marginally inhibited growth in cells with forced
expression of ERa and a greater inhibitory effect with forced
expressionofFOXA1.Therewasunalteredgrowthincellswith
expression of GATA3. Co-expression of ERa and FOXA1; ERa
and GATA3 exhibited inhibition of cell proliferation as
compared with control cells. However, the co-expression of
ERa together with FOXA1 and GATA3 resulted in marked
induction of cell proliferation under E2 stimulation as assessed
by either growth detection assays (Figure 6A; Supplementary
Figures S7 and S8). We have recapitulated this cellular
reprogramming in another ERa-negative breast cancer cell
line, BT-549 and observed similar growth inhibition in BT-549
cells expressing ERa and FOXA1 individually (Supplementary
Figures S9 and S10). We found minor induction of growth in
GATA3-expressing BT-549 cells; however, this growth was
independent of E2 stimulation. However, like MDA-MB-231
cells, we were able to induce E2-dependent growth in
ERaþFOXA1þGATA3-expressing BT-549 cells (Figure 6B;
Supplementary Figure S11). This suggests that only with the
fullactivationofconjointbindingsitesbythethreeTFswillthe
proliferativephenotype associated with ligand induced ERa be
manifest. This further suggests that like induced pluripotent
stem cells (iPS cells) only the combination of multiple factors
(in this case, ERa, FOXA1, and GATA3) can transcriptionally
reprogramme MDA-MB-231 and BT-549 cells to be estrogen
responsive for growth. To assess the nature of this transcrip-
tional reprogramming, we asked the question if the repro-
grammed MDA-MB-231 cells display any similarity in the
expression proﬁle of the ERa-positive breast cancer cell line,
MCF-7. We combined the E2-regulated genes from these
differently transfected MDA-MB-231 cells, and compared their
expression in these MDA-MB-231-transfected cells and MCF-7
cells. Strikingly, taking all differentially expressed genes in
MDA-MB-231 sublines, we found that the expression proﬁle of
E2-induced ERaþFOXA1þGATA3-expressing MDA-MB-231
cells display a good positive correlation (R¼0.42) with
the E2-induced expression proﬁle of MCF-7. By contrast,
we observed a negative correlation between the expression
proﬁles of MDA-MB-231 transfected with ERa only (R¼ 0.21)
(Figure 6C and D; see Supplementary Table X for detailed
analyses). In addition, when only cell-cycle, DNA replication,
and proliferation genes were examined, again, there was
positive correlation between MDA-MB-231 transfected with
ERaþFOXA1þGATA3 and MCF-7 but no correlation between
ERa-only MDA-MB-231 cells and MCF-7 (Supplementary
Figure S12). Speciﬁc genes previously known to be E2
regulated in ERa-responsive cell lines (Frasor et al, 2003;
Fullwood et al, 2009) such as CCND1, STC2, ADCY9, and BTG1
were alsoregulatedin thesamedirectionby ligand in thetriple
factor transfected MDA-MB-231 cells (Supplementary Table
XI). Using the Ingenuity Pathway Analysis, we observed that
the estrogen-responsive genes regulated in MDA-MB-231
transfectant cells were signiﬁcantly associated with cell-cycle,
cellular proliferation, and DNA replication functionalities
(P-value¼7.27E 12–1.28E 04, see Supplementary Figure
S13A). Moreover, we found that there is upregulation of pro-
proliferative cell-cycle genes in the ERaþFOXA1þGATA3-
expressing MDA-MB-231 cells compared with ERa-only cells
(Supplementary Figure S13B). Taken together, these
results suggest that the presence of ERa, FOXA1, and GATA3
has transcriptionally reprogrammed the ERa-negative
Figure 5 The impact of enhanceosome on gene regulation. (A) The association of ERa, FOXA1, and GATA3 bindings with E2-regulated genes. The percentages
of the upregulated and downregulated genes are signiﬁcant from genes associated with ERaþFOXA1þGATA3 overlapped binding sites. (B) The association of
TF bindings with E2-regulated genes in two different conﬁgurations where conjoint ERaþFOXA1þGATA3 bindings with overlapping occupancy by all three TFs and
those non-overlapping individual ERa, FOXA1, and GATA3 bindings in close proximity within 20kb of a TSS. (C) Gene ontology analysis of genes associated with
different categories of ERa, FOXA1, and GATA3 bindings. The genes associated with ERaþFOXA1þGATA3 overlapped binding sites have signiﬁcant functions,
compared with genes only with individual unique ERa, FOXA1, and GATA3 bindings. (D) The presence of ERa, FOXA1, and GATA3 has induced the luciferase activity
of GREB1 gene in MDA-MB-231 cells. The basal luciferase activity of GREB1 in MDA-MB-231 cells is used as the control reference. Mean values of three independent
experiments are compared and standard errors are shown. (E) The loss of FOXA1and/or GATA3 bindings has reduced the luciferase activity of GREB1 gene in MCF-7
cells. ‘mER’, ‘mFOXA1’, and ‘mGATA3’ denote mutated ERE, FOXA1, and GATA3 motif sequences around their respective binding sites near the GREB1 promoter.
The basal luciferase activity of GREB1 in MCF-7 wild-type cells is served as the control reference. Mean values of three independent experiments are compared and
standard errors are shown.
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recapitulating the estrogen-responsive cassette and manifest-
ing the proliferative phenotype.
Finally, we asked if the reprogrammed MDA-MB-231 cells
have acquired luminal cell characteristics. We investigated the
expression of luminal and basal markers genes deﬁned by Kao
et al (2009) in the transfected MDA-MB-231 cells. The analysis
revealed a modest but discernible induction of luminal
markers genes and suppression of basal marker genes in the
ERaþFOXA1þGATA3-expressing MDA-MB-231 cells as com-
paredwiththeERaonlyorvectorcontrolcells(Supplementary
Figure S14; Supplementary Table XII). Moreover, we found
that 63% of the luminal genes are associated with conjoint
binding of the three TFs ERaþFOXA1þ GATA3 within 20kb
of the TSS, and only 13% of these luminal genes showing no
proximitybindingofanyofthesethreeTFs.Ontheotherhand,
24% of the basal genes are associated with proximate conjoint
ERaþFOXA1þGATA3 binding with 40% of these genes are
R = 0.42
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Figure 6 FOXA1 and GATA3 are essential components of E2-induced ERa-response casette. (A) The growth of MDA-MB-231 cells transfected with different
combinations of TFs relative to the vehicle-treated MDA-MB-231 vector control cells at the ﬁnal day of WST-1 measurement. (B) The recapitulation of reprogramming
workinanotherERa-negativeBT-549cells.ThegrowthofBT-549cellstranfectedwithdifferentcombinationsofTFsrelativetothevehicle-treatedBT-549vector control
cellsattheﬁnaldayofWST-1assay.(C)ThecomparisonofgeneproﬁlesinthereprogrammedMDA-MB-231andMCF-7cells.ThegeneproﬁlesofERa-onlyMDA-MB-
231 cells show weak correlation with the expression proﬁles of MCF-7 cells. (D) The ERaþFOXA1þGATA3-expressing MDA-MB-231 cells display good correlation
with the expression proﬁle of ERa-positive MCF-7 cells. The P-value for the differences between the two correlation coefﬁcient stated in (C) and (D) is p2.08E 11.
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(seeSupplementaryFigureS15andSupplementaryTableXIII).
This suggests that ERaþFOXA1þGATA3 binding exerts
greater impact on regulating the transcription of luminal
markergenes as comparedwith the basal markergenes.Taken
together, we demonstrate that the co-expression of the ERa
enhanceosomecomponents,namelyERa,FOXA1,andGATA3,
is required to approximate the appropriate luminal expression
cassette.
Discussion
ER, as a prototype of a nuclear hormone receptor, mediates a
broad range of cellular and physiologic functions with organ
and context speciﬁcity. The most proximate form of regulatory
control resides in the protein–DNA interaction of TF binding
to their cognate recognition motifs and modiﬁed by
cofactors. However, genome-wide studies of ERa binding
show a dispersed occupancy pattern at binding sites bearing
heterogenous recognition motifs that are, at the sequence
level, also not well conserved in evolution (Kunarso et al,
2010). This binding site heterogeneity is normalized by
chromatin looping to bring these distant and distributed
enhancers in proximity to the regulated TSS (Fullwood et al,
2009). Herein, we show that FOXA1 and GATA3 are essential
for optimal ERa binding to DNA, that FOXA1 and GATA3 are
recruitedasacomplextothemostfunctionalERabindingsites
after ligand activation, and that the binding of this tripartite
enhanceosome complex of ERa, FOXA1, and GATA3 is
necessary for optimal transcriptional activation in reporter
gene assays. The enhanceosome assembly is recruited to sites
bearingthe threerecognitionmotifs suggests that this complex
formation is ‘hard-wired’ in the human genome and provides
an evolutionary advantage. This notion is supported by the
fact that the colocalization of the motifs for these TFs was
found in 23090 sites in the reference human genome, but in
only 360 sites in a random nucleotide sequences for a 64-fold
enrichment. This compares with an B18-fold enrichment
for the ERE alone suggesting a strong evolutionary selection
for the three TFs to be colocalized (see Supplementary
Figure S16).
An enhanceosome has been deﬁned as protein complex
composed of a repertoire of TFs that binds to the ‘enhancer’
region of a gene and sequentially recruits components of
the transcriptional machinery such as RNA polymerase to
initiate the gene’s transcription. Synergistic interplay among
the members within the enhanceosome complex results in
providingsomefunctionalspeciﬁcity,andamultiplegene‘fail-
safe’ mechanism for controlling gene expression (Robert and
Tom,1994).Itissuggestedthatanenhanceosomemayprovide
functional redundancy that minimizes the chances that a gene
may be switched off due to mutation, or permit activation of a
gene by orchestrating multiple different signaling cascades
(Farnham,2009). Theimportance ofenhanceosomeformation
is evidenced by the virus-inducible transcriptional activation
of the human interferon-b (IFN-b) gene by the assembly
oftranscriptionalactivator(p50/p65),IRF-1,ATF-2,c-Jun,and
high mobility group protein HMG I to the basal transcription
complex (Thanos and Maniatis, 1995). Chen et al (2008)
showed that TFs coordinately expressed in embryonic stem
cell differentiation form speciﬁc enhanceosomes adjacent to
cassettes of genes that demarcate different developmental
functions. The present study provides evidence of how the
ERa, FOXA1, and GATA3 enhanceosomes regulate this multi-
faceted transcriptional network operative in reproduction and
cancer. Furthermore, we show that this ERaþFOXA1þ
GATA3 enhanceosome recruits distinct components of active
transcription regulatory machinery, namely RNA Pol II and
p300,anacetyltransferaseassociatedwithenhanceractivityas
well as chromatin opening. Interestingly, the ERa, FOXA1, and
GATA3 binding were also coincided with retinoic acid receptor
binding though the overlap is less frequent, suggesting
that FOXA1 and GATA3 could have a broader ‘universal’
co-regulator function for nuclear hormone binding (Hua
et al, 2009).
It is known that FOXA1 and GATA3 are important regulatory
proteins in their own right. FOXA1 has winged helix domains
that can structurally mimic histone H1 and H5, and thus
permits its interaction with histone H3 and H4. This unique
feature of FOXA1 allows it to bind to the speciﬁc DNA
sequences on the nucleosome core and displace the linker
histones, leading to de-compaction of chromatin and to
facilitate the binding of other TFs (Clark et al, 1993; Cirillo
et al, 1998; Kaestner, 2000). It is suggested that ERaþFOXA1-
regulated network establishes an ‘one-step forward’ (through
cyclinD1induction)and‘one-stepbackward’(throughp27
KIP1
induction) manner to control cell-cycle progression in breast
cancer cells (Nakshatri and Badve, 2009). Recent work by
Lupien et al (2008) revealed that there was signiﬁcant overlap
of FOXA1 occupied sites on ERa cistrome, hence suggesting
that FOXA1 contributed in the control of E2 signaling in breast
cancer cells. In accordance with the report by Bernado et al
(2010), we have found that siRNA-mediated knockdown
of ERa reduces the levels of FOXA1 in MCF-7 cells, and
similar attenuation of FOXA1 reduces the levels of ERa (data
not shown).
GATA3 has essential roles in the mammary gland morpho-
genesis and lactogenesis. Inactivation of GATA3 resulted in
diminished mammary epithelial structure, severely impaired
lactogenesis and disrupted differentiation of luminal progeni-
tor cells into ductal and alveolar cells (Asselin-Labat et al,
2007). Moreover, GATA3 is also involved in the positive
crossregulatory loop with ERa in breast cancer cells in
mediating the E2 signaling (Eeckhoute et al, 2007). Clinically,
both FOXA1 and GATA3 are known to be co-expressed in ER-
positive breast cancers. In addition, Mehra et al (2005)
reported that low levels of GATA3 were strongly associated
with larger tumor size, positive lymph node status, higher
histologygrade,ERa-negativestatus,Her2-neuoverexpression
as well as increased risk for recurrence and metastasis.
Taken together, we posit that such a complex regulatory and
functional interaction of three TFs each subserving important
functions is another evolutionary strategy to ensure the
balanced co-regulation of gene networks important in mam-
malian reproduction.
Here, we have shown that the effects of the ERaþ
FOXA1þGATA3 enhanceosome expression are the regulation
of the major important E2-responsive genes associated with
various signaling pathways, biology processes, and molecular
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presence of an ERa is necessary for E2-induced growth in
responsive cells, its presence is not sufﬁcient for cellular
proliferation, and in fact, the introduction of ERa or FOXA1
into ERa-negative cell lines such as MDA-MB-231 leads to cell-
cycle arrest. Importantly, we show that transfection of the
three TFs into the ERa-negative cell line, MDA-MB-231, could
reprogram the cell to be estrogen responsive for cell prolifera-
tion, counteracting the growth inhibitory action of unaided
FOXA1 or ERa. This cellular reprogramming is correlated with
reconstruction of the approximate transcriptional cassette
of the modiﬁed MDA-MB-231 to partially resemble that of
E2-stimulated MCF-7 cells. Thus, it appears that the primary
role of FOXA1 and ERa alone in breast cancer cells is as a
growth or tumor inhibitor, but that the conditional expression
of ERa, FOXA1, and GATA3 reverses this state to that of growth
induction.
Intriguingly, enforced expression of the triple factors, ERa,
FOXA1, and GATA3, also induced a modest basal to luminal
expressioncassettechangebyreducingthebasalsignatureand
increasing theluminal signature in MDA-MB-231 cells not seen
in the ERa alone-transfected clone. Our resultssuggest that the
conjoint effects by the three TFs could formulate a luminal
cassette and then manifest the proliferative phenotype in
response to estrogen stimulation.
Our work also sheds some light on the functional role of
FOXA1 which is thought to be a pioneering factor for nuclear
hormone receptors such as the ER and androgen receptor
(Carroll et al, 2005). As a pioneering factor, FOXA1 may
function to open chromatin structures so as to facilitate ERa
binding to its cognate response elements. Indeed, our
chromatin model predictive of ERa binding includes FOXA1
occupancy in the preligand (before E2 exposure) state (Joseph
et al, 2010). However, these studies did not examine the
dynamicrelationshipofERaandFOXA1occupancybeforeand
after ligand exposure. Our results suggest that ERa is as likely
to be a pioneering factor to recruit FOXA1 as the converse.
Recently, Eeckhoute et al (2009) reported that a signiﬁcant
fraction of FOXA1-bound sites have a relatively closed
chromatin conformation that is unrelated to gene expression,
suggesting that FOXA1 may require a repertoire of collaborat-
ing TFs to promote chromatin opening. Our ﬁndings suggest
that ERa is one such collaborating TF with GATA3 playing a
more minor role.
Taken together, we have uncovered the functional impor-
tance of an enhanceosome comprising ERa, FOXA1, and
GATA3 in the estrogen responsiveness of ERa-positive breast
cancer cells. This enhanceosome exerts signiﬁcant combina-
torial control of the transcriptional network regulating
growth and proliferation of ERa-positive breast cancer cells.
Materials and methods
ChIP assay
The ChIP assays were carried out as described previously (Lin et al,
2007).Brieﬂy,theserum-depletedMCF-7cellsweretreatedwith10nM
E2 or vehicle control for 45min. Cells were crosslinked with 1%
formaldehyde for 10min at room temperature, followed by 125mM
glycine treatment to inactivate the crosslinking. Chromatin extracts
were fragmentized to an average size of 500bp with sonication,
followed by overnight immunoprecipitation at 41C. The protein–DNA
complex was de-crosslinked with overnight incubation at 651C. DNA
extraction was performed and qPCR validation was carried out using
SYBR Green chemistry. The ChIP samples were then subjected to
ChIP-seq on Solexa platform. Antibodies used in these ChIP experi-
ments are listed in Supplementary Table IV.
Binding sites analysis
The short reads from ChIP-seq libraries were aligned to the human
genome hg18 using Batman with at most two mismatches, and only
the uniquely mapped reads were extracted for further analysis. The
ChIP-seq for ERa, FOXA1, RNA pol II, and FAIRE libraries have been
described in Joseph et al (2010). Here, we used the Model-based
Analysis for ChIP-Seq (MACS) to call the peaks for all the three TFs
(Zhang et al, 2008) with default parameters. The peaks were reported
as the summit of the enriched regions. The number of binding sites
for each ChIP-seq library is shown in Supplementary Table I. The
binding sites were validated with qPCR using the speciﬁc primer sets.
The primers are designed around the binding sites and qPCR
was performed using SYBR Green Chemistry and 5mM of primers
(listed in Supplementary Table VII) in ABI7500 Read-time PCR System
(Applied Biosystems).
The overlap of peaks from two libraries is deﬁned as the peaks
withingenomicdistance200bp.Themotifscanningwasdonewiththe
program CentDist (Zhang et al, 2011) with motif PWM from
TRANSFAC version 11.3 (Matys et al, 2003) with FDRo1E 3.
Sequential ChIP
TheChIPassaywascarriedoutasdescribedpreviously.Theelutefrom
the ﬁrst round of immunoprecipitation with ERa antibody was
subjected to second round of immunoprecipitation using FOXA1 and
GATA3, respectively, followed by qPCR to validate co-occupancy of
ERaþFOXA1 and ERaþGATA3 to the target sites. The primers used
for Re-ChIP are listed in Supplementary Table V.
Cells synchronization
The MCF-7 cells were grown in phenol red-free DMEM with 5%
charcoal dextran-treated FBS (CDFBS) for 3 days before subjecting to
2.5mM a-amanitin treatment for 2h. The cells were washed with PBS
twice, followed by E2 or vehicle control treatment for 45min. Cells
were harvested at the 5-min interval and subjected to ChIP-qPCR
assays. The primers used to study the progressive recruitment of ERa
and FOXA1 are listed in Supplementary Table VI.
Microarray gene expression study on MCF-7 cells
TheMCF-7cellsweregrowninphenolred-freeDMEMwith5%CDFBS
for3daysbefore E2 stimulation.TotalRNAwasharvestedat3,6,9,12,
24, and 48h after E2 treatment using RNeasy Kit (Qiagen). The quality
of RNA samples was veriﬁed with Bioanalyzer before proceeding to
Affymetrix microarray experiments. The microarray data from E2
stimulation were normalized against the data with vehicle treatment,
log-transformed, and median normalized. The upregulated and
downregulated genes were called with 1.2-fold change (which
corresponds to 0.263 after log2 transformation).
Microarray gene expression study on the
transfected MDA-MB-231 cells
The transfected MDA-MB-231 cells were grown in phenol red-free
RPMI with 5% CDFBS before subjecting to E2 stimulation. Total RNA
was harvested at days 2 and 10 using RNeasy Kit (Qiagen) and labeled
using the TargetAmpt Nano-gt Biotin-aRNA Labeling Kit (Epicentre)
before proceeding to Illumina microarray experiment. The microarray
datafromE2stimulationwerenormalizedagainstthedatawithvehicle
treatment, log-transformed, and median normalized. The upregulated
and downregulated genes were called with 1.2-fold change.
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The binding sites were associated with the nearest TSSs within 20kb
(see Supplementary information for detailed description).
Site-mutagenesis experiments
The promoter region of GREB1 gene was cloned into pGL4-luciferase
construct using the In-fusion kit (Clontech). Several primers with the
mutated ERa, FOXA1, and GATA3 binding motifs were designed and
mutagenesis experiment was carried out with Stratagene Site-directed
Mutagenesis Kit. The sequences of the GREB1-luc construct as well as
the mutated-luc constructs were veriﬁed with sequencing.
Expression clones
The expression clones encoding ESR1, FOXA1, and GATA3 were
purchased from Genecopoeia and veriﬁed by sequencing.
Luciferase reporter assays
The MDA-MB-231 cells were transfected with the reporter construct
together with different combination of TFs. The MCF-7 cells were
transfected with the reporter construct together with the mutated ERa,
FOXA1, and GATA3 constructs. A Renilla luciferase plasmid was co-
transfected as an internal control. Dual-luciferase reporter kit
(Promega) was employed to measure the luciferase activity relative
renilla activity using GloMax 96 microplate luminometer (Promega).
Transfection experiments
The MDA-MB-231 and BT-549 cells were stably transfected with ERa,
FOXA1, and GATA3 using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instructions. An empty vector transfection was
included as a negative control. The G418-selected clonal cells were
veriﬁedfortheirERa,FOXA1,andGATA3expressionwithwesternblot
usingERa (sc-543,Santa-Cruz), FOXA1(ab-5089,Abcam),andGATA3
(sc-269, Santa-Cruz) antibodies at the dilution of 1:500.
Cell proliferation assays
The transfected MDA-MB-231 and BT-549 cells were seeded in 96-well
plate and subjected to 10nM E2 or vehicle treatment. The culture
media were changed every 3 days and the cell proliferation was
assayed with WST-1 (Roche) using Sunrise microplate absorbance
reader system (Tecan). Another cell growth assay assessed by cell
number count was performed. The cells are ﬁxed with 4%
paraformaldehyde followed by permeabilization with 0.1% Triton-X
at room temperature. The cells were then stained with 2.5mg/ml of
Hoechst for 10min before proceeding to cell counting scan on
Cellomics ArrayScan VTi machine (Thermo Scientiﬁc).
Data release
The raw ChIP-seq sequences and processed data can be accessed
from NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/) with accession
number GSE23701, GSE23893, GSE26831, and GSE29073. The gene
expression data can be accessed from NCBI GEO (http://
www.ncbi.nlm.nih.gov/geo/) with accession number GSE30574.
Supplementary information
Supplementary information is available at the Molecular
Systems Biology website (www.nature.com/msb).
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